A former Celgene Corp. saleswoman who blew the whistle on allegedly improper marketing tactics at the drug company was cleared Tuesday to collect a $78 million bounty that’s been held up amid a dispute between whistleblower attorney Reuben Guttman and his former law firm, Grant & Eisenhofer.

U.S. District Judge Philip Gutierrez in Los Angeles agreed to strike down an attorney’s charging lien that Grant & Eisenhofer asserted against a whistleblower award heading to Beverly Brown, a former Celgene employee who brought a False Claims Act lawsuit against the company. Brown’s false claims suit alleged that Celgene promoted a pair of cancer drugs, Thalomid and Revlimid, for off-label uses that weren’t approved by the U.S. Food and Drug Administration.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]